Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2020

Alterations in plasma triglycerides and ceramides: Links with
cardiac function in humans with type 2 diabetes
Linda R. Peterson
Washington University School of Medicine in St. Louis

Xuntian Jiang
Washington University School of Medicine in St. Louis

Ling Chen
Washington University School of Medicine in St. Louis

Anne C. Goldberg
Washington University School of Medicine in St. Louis

Marsha S. Farmer
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Peterson, Linda R.; Jiang, Xuntian; Chen, Ling; Goldberg, Anne C.; Farmer, Marsha S.; Ory, Daniel S.; and
Schaffer, Jean E., ,"Alterations in plasma triglycerides and ceramides: Links with cardiac function in
humans with type 2 diabetes." Journal of Lipid Research. 61,7. . (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9281

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Linda R. Peterson, Xuntian Jiang, Ling Chen, Anne C. Goldberg, Marsha S. Farmer, Daniel S. Ory, and Jean
E. Schaffer

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/9281

Alterations in plasma triglycerides and ceramides: links
with cardiac function in humans with type 2 diabetes
Linda R. Peterson,1,* Xuntian Jiang,* Ling Chen,† Anne C. Goldberg,§ Marsha S. Farmer,*
Daniel S. Ory,* and Jean E. Schaffer**
Division of Cardiology, Department of Medicine,* Division of Biostatistics,† and Division of Endocrinology,
Department of Medicine,§ Washington University School of Medicine, St. Louis, MO 63110; and Joslin
Diabetes Center,** Harvard Medical School, Boston, MA 02215

Abstract Cardiac dysfunction in T2D is associated with excessive FA uptake, oxidation, and generation of toxic lipid
species by the heart. It is not known whether decreasing lipid
delivery to the heart can effect improvement in cardiac function in humans with T2D. Thus, our objective was to test the
hypothesis that lowering lipid delivery to the heart would result in evidence of decreased “lipotoxicity,” improved cardiac function, and salutary effects on plasma biomarkers of
cardiovascular risk. Thus, we performed a double-blind randomized placebo-controlled parallel design study of the effects of 12 weeks of fenofibrate-induced lipid lowering on
cardiac function, inflammation, and oxidation biomarkers,
and on the ratio of two plasma ceramides, Cer d18:1 (4E)
(1OH, 3OH)/24:0 and Cer d18:1 (4E) (1OH, 3OH)/16:0
(i.e., “C24:0/C16:0”), which is associated with decreased
risk of cardiac dysfunction and heart failure. Fenofibrate
lowered plasma TG and cholesterol but did not improve
heart systolic or diastolic function. Fenofibrate treatment
lowered the plasma C24:0/C16:0 ceramide ratio and minimally altered oxidative stress markers but did not alter
measures of inflammation. Overall, plasma TG lowering correlated with improvement of cardiac relaxation (diastolic
function) as measured by tissue Doppler-derived parameter
e′. Moreover, lowering the plasma C24:0/C16:0 ceramide ratio was correlated with worse diastolic function. These findings indicate that fenofibrate treatment per se is not sufficient
to effect changes in cardiac function; however, decreases in
plasma TG may be linked to improved diastolic function.
In contrast, decreases in plasma C24:0/C16:0 are linked with
worsening cardiac function.—Peterson, L. R., X. Jiang, L.
Chen, A. C. Goldberg, M. S. Farmer, D. S. Ory, and J. E.
Schaffer. Alterations in plasma triglycerides and ceramides:
links with cardiac function in humans with type 2 diabetes. J.
Lipid Res. 2020. 61: 1065–1074.
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T2D is associated with an increased risk of heart failure
in the absence of obstructive coronary heart disease
(CHD), valvular abnormalities, alcoholism, or hypertension. Asymptomatic left ventricular (LV) diastolic dysfunction can be detected in up to 75% of people with T2D even
in the absence of comorbidities (1, 2). Furthermore, systolic
abnormalities including diminished mid-wall fractional
shortening (FS) and peak systolic strain are present in up to
16% of asymptomatic patients (3–5). Unfortunately, asymptomatic cardiac dysfunction in patients with T2D can progress to clinical heart failure and “diabetic cardiomyopathy”
(6, 7). There is a need to identify effective clinical measures
that improve myocardial function or prevent progression to
symptomatic heart failure in patients with T2D.
Studies of rodent models of T2D provide evidence that
lipotoxicity is caused by increased plasma FFA and TG delivery to and oxidation/storage by the heart, which leads to
oxidative stress and significantly contributes to risk of cardiac dysfunction (8–13). In addition to serving as an important cardiac energy source, FFAs are substrates for de novo
biosynthesis of ceramides, complex lipids containing a
sphingosine backbone coupled to fatty acyl chains (14).
The supply of FFAs and a family of ceramide synthase enzymes with distinct but overlapping FFA substrate specificities and the supply of FFAs govern production of ceramide
molecular species with differing acyl chain lengths. Perturbation of the distribution of ceramide molecular species
promotes lipotoxicity in cultured cardiomyocytes (15). In
the myocardium of T2D animal models and in models of

Abbreviations: CHD, coronary heart disease; FS, fractional shortening; HbA1c, hemoglobin A1c; 1H-MRS, 1H-magnetic resonance spectroscopy; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin 6;
LV, left ventricular.
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MATERIALS AND METHODS
We chose treatment with fenofibrate for this interventional trial
because it has been shown to effectively lower plasma TG, even in
subjects treated with statin medications for hypercholesterolemia
(33, 34). We assessed the effect of adding fenofibrate to the existing
medical regimens of subjects with T2D who were not already taking
fibrates. There was protocol approval from the Institutional Review
Board of Washington University School of Medicine. Informed
consent was obtained from the human subjects or their representatives, and the study abides by the Declaration of Helsinki principles.
All subjects underwent a history and physical exam, stress echocardiography, and phlebotomy for eligibility screening.

Subjects
Subjects were recruited from the St. Louis metropolitan area.
In order to minimize possible confounding effects on cardiac
function, subjects were excluded if they were <30 or >65 years
old, smoked, performed >3.5 h/weekk rigorous cardiovascular
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exercise, had a blood pressure 140/90 mm Hg, atrial fibrillation, evidence of CHD on screening stress echocardiography,
heart failure, hemoglobin A1c (HbA1c) >10%, recreational drug
or severe alcohol use, history of liver disease, renal dysfunction
(creatinine >1.5 mg/dl), use of anticoagulants, presence of paradoxical septal motion or more than mild valvular heart disease, or
evidence for pericardial or infiltrative myocardial diseases.
Women who were pregnant or lactating were also excluded. Subjects were instructed to continue on their usual medications, including lipid-lowering therapy throughout the study.

Randomization
Subjects were randomized (using randomization.com to create
block randomization) in a blinded fashion to treatment with fenofibrate (160 mg/day) or identical-appearing placebo for 12 weeks.
Subjects were instructed to continue their usual level of physical
activity and an ATPIII diet consistent with American Diabetes Association recommendations. At the end of the intervention, 1Hmagnetic resonance spectroscopy (1H-MRS) imaging of liver was
repeated to assess the effects of intervention on systemic lipid exposure, and fasting blood and echocardiographic studies were
repeated. Study physicians provided medical monitoring throughout the intervention to ensure safety of the participants, with interim monthly visits for history and pill counts to assess compliance.
Study subjects recorded blood glucose concentrations daily,
which were reviewed at monthly visits, and kept an acute event
log, since TGs are acute phase reactants.

Plasma/serum/urine measurements other than ceramides
Plasma insulin was measured using a sandwich electrochemiluminescence immunoassay and a Roche Cobas c601 analyzer, Basel, Switzerland). Plasma glucose levels were measured using
enzymatic colorimetric assays on the Roche c501 analyzer (Roche
Diagnostics, North America). After a 12 h fast, HDL, TG, and total
cholesterol levels were measured from plasma using enzymatic
colorimetric assays run on the Roche c501 analyzer. HbA1c was
measured in whole blood samples using a turbidimetric inhibition immunoassay run on the Roche c501 analyzer. Glycated serum protein was measured using kits from Diazyme, and albumin
was measured using kits from Roche Diagnostics, both on a Roche
cobas c501. Serum FFAs were quantified using a WAKO colorimetric kit, and systemic inflammatory markers [high sensitivity
C-reactive protein (hsCRP), TNF-, and interleukin 6 (IL-6) were
quantified using reagent kits from Roche Diagnostics]. Markers of
oxidative stress (hexanoyl-lysine, propanoyl-lysine) were quantified in plasma and urine samples by LC-MS/MS (35–37).

Plasma ceramides
Plasma Cer d18:1 (4E) (1OH, 3OH)/24:0 and Cer d18:1 (4E)
(1OH, 3OH)/16:0 were analyzed using an ABI 4000 QTRAP LCMS/MS tandem quadrupole mass spectrometer with a linear ion
trap interfaced to a Shimadzu high-performance LC system. Because the assay measured endogenous analytes in plasma, we compared the concentration-response of the analyte in a surrogate
matrix (e.g., 5% BSA) to that of plasma samples. To determine
recovery, the plasma or surrogate matrix was spiked with differing
amounts of d4-C22:0 and d4-C24:0, extracted with chloroform/
methanol and analyzed as above. Differences in matrix effects and
extraction recoveries were compensated by internal standards.
Details of the metabolomic analytical methods used were previously reported by our group (38).

Body composition and liver fat measurement
Subjects underwent baseline anthropomorphic and metabolic
phenotyping with dual-energy X-ray absorptiometry analysis for
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lipid overload-induced cardiac function, total ceramides
are elevated (11, 16–18). The observation that inhibition of
de novo ceramide synthesis in these models improves cardiac function implicates this class of lipids as important mediators of lipotoxicity (18–20). Lipid-induced inflammation
and oxidative stress have also been shown to contribute to
LV dysfunction in rodent models (21–24).
Abnormalities of lipid metabolism in diabetes have also
been associated with LV dysfunction in humans. In the
Multiethnic Study of Atherosclerosis, incident heart failure
in participants with diabetes was increased and was highest in
diabetic subjects with hypertriglyceridemia (25). Increased
plasma FFA concentrations in T2D upregulate myocardial
FFA uptake, utilization, and oxidation, and steatosis (26–29).
This metabolic pattern is associated with decreased efficiency,
impaired energetics, and diastolic dysfunction (2, 26). Nonetheless, it has been difficult to causally link myocardial lipid
overload to myocardial dysfunction in humans with diabetes.
In the ACCORD lipid trial, the trend for lower rates of fatal
or nonfatal congestive heart failure in the fenofibrate-treated
versus placebo group was not significant (30), and cardiac
function was not quantified as an outcome. More recently,
the REDUCE-IT trial revealed lower hazard ratios for a composite cardiovascular end point in both diabetic and nondiabetic subjects, but myocardial function and heart failure were
not reported as separate outcomes (31).
The purpose of this study was to test whether lowering
lipid delivery to the heart improves cardiac function in human subjects with T2D. We employed a randomized, double-blinded trial design in which subjects were treated with
fenofibrate or placebo. In addition to echocardiographic
endpoints, we evaluated changes blood-based markers of
ceramide metabolism, inflammation, and oxidative stress.
We were particularly interested in the plasma ratio of Cer
d18:1 (4E) (1OH, 3OH)/24:0 and Cer d18:1 (4E) (1OH,
3OH)/16:0 (i.e., C24:0/C16:0 for brevity). This biomarker
is increased in patients with end-stage heart failure and improves following treatment with LV assist devices (20). Furthermore, this ratio is inversely associated with incident
heart failure in community-based populations (32).

determination of body composition (iDXA; GE Healthcare, Madison, WI). 1H-MRS for quantification of hepatic TG used 1.5 T
Avanto or a 3 T Trio scanner, a PRESS sequence without water
suppression and breath-hold techniques (39). Liver fat percentage was calculated as area under the lipid peak (methyl and methylene resonances) divided by the sum of area under water and
lipid peaks, with correction for T2 relaxation.

Echocardiography

Statistical analysis
SAS version 9.4 (SAS Inc, Cary, NC) was used for data analyses.
The primary endpoint was change in systolic function as quantified by FS and diastolic function as quantified by e′. The secondary endpoint was change in plasma C24:0/C16:0 ceramide ratio.
Other cardiac, inflammatory, and oxidative stress endpoints were

RESULTS
The CONSORT diagram (Fig. 1) outlines the recruitment, enrollment, screen failures, drop-outs, and those

Fig. 1. A CONSORT diagram depicting enrollment
flow, drop-outs, and reasons for drop out.
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Cardiac structure and function were assessed using 2D-, Doppler, tissue Doppler, and strain echocardiography according to
guidelines from the American Society of Echocardiography (40,
41). FS, a measure of systolic function, and tissue Doppler-derived
e′, a measure of diastolic function, were primary outcome variables. Although our study was not powered to evaluate global longitudinal strain measures as endpoints, data using these approaches
were analyzed in an exploratory fashion, as these newer techniques
may be more sensitive to detect dysfunction (42). It should be
noted that global longitudinal strain could be analyzed in only 27
subjects in the placebo group and 29 subjects in the fenofibrate
group due to acoustic window limitations in some subjects.

tertiary endpoints. Two-sample t-tests were used for comparing
continuous variables between groups and Chi-square tests were
used for categorical variables. Satterthwaite analysis was performed if variables had unequal variances. For comparison of the
proportion of subjects taking certain medications, two-sample Z
test for proportions was used. One sample t-tests were used to
compare means of the deltas of the endpoints. ANCOVA was used
for comparison of the change in the endpoints between the
groups after adjustment for predetermined baseline variables including age, sex, race, body fat percent, BMI, diastolic blood pressure, HbA1c, systolic blood pressure, fasting glucose, fasting TG,
ethnicity, and hsCRP. Pearson correlation coefficients were determined between the change in TGs and the cardiac endpoints as
well as among the  TGs,  liver fat, and  C24:0/C16:0 ceramide
ratio. Shapiro-Wilk tests for normality of distribution were performed and appropriate data transformations were used when
needed. Outlier values were determined using the rule that defines
an outlier as a value larger than three times of interquartile range
from the 75% percentile or smaller than three times of interquartile
range from the 25% percentile, and outliers were removed from
analysis as noted in the legends. Data are reported as mean ± SD. All
statistical analyses were two-sided at significance level 0.05.

who finished the study. In short, of the 70 subjects randomized to fenofibrate (n = 34) or placebo (n = 36), 65 completed the study (31 in the fenofibrate group). Reasons for
noncompletion included rash and pruritis (n = 2), elevated
liver function tests (n = 1), unrelated health issue (n = 1),
and noncompliance (n = 1).

Effects of 12 weeks of fenofibrate/placebo intervention
on anthropomorphic, metabolic, hemodynamic, and
oxidative stress and inflammation markers
Changes in anthropomorphic and metabolic characteristics, inflammatory and oxidative stress markers, and hemodynamics from post-to-pre-intervention are shown in Table 4.
Importantly, there were no significant differences in BMI or
diabetes control between the fenofibrate and placebo
groups during the intervention period, as measured by glycated albumin, fasting insulin, and fasting glucose. Similarly, it is important to note that there were no differences
between the changes in the two groups’ hemodynamics
(heart rate, blood pressure), because these variables can
effect a change in cardiac function measurements.
To evaluate evidence for oxidative stress, we focused
on the products of the reaction of oxidized lipids
with lysine residues in proteins, N-(hexanoyl)- and N(propanoyl)-lysine, which have been shown to be stable
markers of oxidative stress in plasma and urine of diabetic
patients (43). There was a significant difference between
the change (post-pre) in the plasma concentration of N(propanoyl)-lysine between the fenofibrate and placebo
groups, with the fenofibrate group having a greater
decrease in the concentration of this marker (Table 4).

TABLE 1. Baseline characteristics

Age (years)
Sex (percent women)
Race (percent white)
2
BMI (kg/m )
Body fat (%)
Liver fat (%)
Total cholesterol (mmol/l)
LDL cholesterol (mmol/l)
HDL cholesterol (mmol/l)
TGs (mmol/l)
Fasting FFAs (mmol/l)
Fasting insulin (pmol/l)
Fasting glucose (mmol/l)
HbA1c percent (mmol/mol)

Normal Range

Placebo (n = 34)

NA
NA
NA
18.5–24.9a
Women, 10–31;
men, 2–25b
c
5.56
d
<3.8
<2.6d
NA
NA
NA
NA
<5.5e
<5.7e

54.4 ± 8.6
64.7
76.5
35.5 ± 5.9
44.7 ± 8.1

54.5 ± 8.6
74.2
77.4
36.9 ± 7.5
46.0 ± 8.5

0.96
0.41
0.62
0.39
0.55

13.76 ± 7.93
4.43 ± 1.06
2.30 ± 0.98
1.14 ± 0.32
2.30 ± 1.00
0.597 ± 0.233
165.44 ± 124.19
7.54 ± 2.49
7.0 ± 1.1
(52.93 ± 12.11)
15.65 ± 3.82
2.48 ± 0.70
0.203 ± 0.043
12.35 ± 3.04
4.08 ± 2.80
1.81 ± 0.66
4.39 ± 6.31
0.16 ± 0.04
3.02 ± 0.67
45.24 ± 23.76
233.4 ± 132.0

15.96 ± 10.08
4.69 ± 0.85
2.56 ± 0.70
1.24 ± 0.34
2.01 ± 1.34
0.622 ± 0.219
206.86 ± 204.58
7.40 ± 1.59
7.1 ± 1.1
(54.30 ± 11.55)
16.21 ± 3.25
2.35 ± 0.61
0.214 ± 0.052
11.21 ± 2.38
6.58 ± 5.18g
1.79 ± 0.51
4.13 ± 1.88
0.16 ± 0.06
3.18 ± 0.63
45.80 ± 25.07
235.74 ± 202.41

0.38
0.27
0.22
0.24
0.32
0.66
0.33
0.79
0.64

Glycated albumin (%)
Ceramide 24:0 (g/ml)
Ceramide 16:0 (g/ml)
Ceramide 24:0/C16:0
hsCRP (mg/l)
TNF- (pg/ml)
IL-6
Plasma N-(hexanoyl)-lysine (ng/mg)
Plasma N-(propanoyl)-lysine (ng/mg)
Urinary N-(hexanoyl)-lysine (ng/mg)
Urinary N-(propanoyl)-lysine (ng/mg)

NA
f
0.735–3.50
0.0612–0.270f
6.43–25.0f
≤3a
NA
NA
NA
NA
NA
NA

Fenofibrate (n = 31)

Data shown are mean ± SD. NA, not available. Bold font indicates a significant P value.
a
Per the Centers for Disease Control (https://www.CDC.gov).
b
Per the American Council on Exercise (https://www.ACEfitness.org).
c
Per (45).
d
Per the American Heart Association (https://www.heart.org).
e
Per the American Diabetes Association (https://www.diabetes.org/a1c).
f
Per (32).
g
Outliers excluded: n = 2.
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P

0.53
0.46
0.36
0.10
0.02
0.88
0.82
0.64
0.30
0.93
0.96
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Baseline characteristics
The characteristics of both groups are shown in Table 1.
The two groups were very similar with no significant differences in age, sex, racial composition, anthropomorphic
and metabolic characteristics, oxidative stress markers, or
hemodynamic measurements. Only one inflammatory
marker, hsCRP, was different, higher at baseline in the fenofibrate group. The placebo group had a slightly lower
relative wall thickness than the fenofibrate group at baseline, but LV mass and volume and systolic (FS, ejection
fraction, global longitudinal strain, tissue Doppler s′ average) and diastolic (e′ average, E/e′ septal) functional
measurements were not significantly different (Table 1).
The proportion of subjects in both groups who were
taking statins, diabetes medications (including insulin),
calcium channel blockers, diuretics, angiotensin enzymeconverting inhibitors/angiotensin receptor blockers, or
-blockers was not different (Table 2). Thus, recruitment and randomization led to entry of highly similar
subjects in treatment and placebo groups. There were

no differences in baseline medications between the groups
(Table 3).

TABLE 2. Baseline hemodynamic and cardiac measures
Normal Range
a

Heart rate (bpm)
60–100
a
Systolic blood pressure (mmHg)
<120
a
Diastolic blood pressure (mmHg)
<80
Mean arterial pressure (mmHg)
<93a
LV mass (g)
Men, 96–200;b women, 66–150b
LV end-diastolic volume (ml)
Men, 106 ± 22;b women, 76 ± 15b
Relative wall thickness
Men, 0.24–0.42;b women, 0.22–0.42b
Ejection fraction (%)
Men, 62 ± 5;b women, 64 ± 5b
FS (%)
18b
Global longitudinal strain (%)c
 21.2 ± 2.4b
NA
s′ average (cm/s)
NA
e′ average (cm/s)
b
<15
E/e′ septal

Placebo (n = 34)

Fenofibrate (n = 31)

P

71.9 ± 8.9
127.2 ± 10.7
78.6 ± 7.5
95.9 ± 7.9
145.9 ± 33.4
88.7 ± 18.6
0.43 ± 0.08
68 ± 5
38 ± 6
17.81 ± 2.1
8.10 ± 1.73
7.99 ± 1.78
10.44 ± 2.83

73.6 ± 10.0
125.9 ± 11.9
75.3 ± 10.1
94.3 ± 7.9
153.3 ± 39.2
86.9 ± 21.0
0.48 ± 0.10
68 ± 6
39 ± 7
17.8 ± 2.56
7.82 ± 1.27
8.30 ± 1.70
10.16 ± 3.69

0.47
0.65
0.14
0.40
0.42
0.72
0.04
0.96
0.61
0.98
0.46
0.48
0.74

Data shown are mean ± SD or minimum–maximum (range of normal). Bold font indicates a significant P value.
a
Per the American Heart Association (https://www.heart.org)
b
Per the American Society of Echocardiography (https://www.asecho.org)
c
Placebo group, n = 27; fenofibrate group, n = 29 due to echocardiographic image limitations.

Specific lipids were significantly affected by fenofibrate
treatment compared with placebo
As expected, fenofibrate lowered plasma TG more than
placebo (P < 0.05; Fig. 2, Table 4). This difference persisted
after multivariable modeling (P = 0.04). This difference was
also maintained after log transformation of the TG (P =
0.003) and in a multivariable model of delta log TG (P =
0.02). Consistent with the known effects of fenofibrate to
enhance lipolysis of TG-rich lipoproteins, subjects receiving
fenofibrate had significantly decreased cholesterol (P =
0.004) and a trend for lower LDL following treatment
(Table 4). The change in plasma FFAs from post- to preintervention, however, was not different between the groups
(Fig. 2) before or after multivariate adjustments.
Lipid delivery to nonadipose tissues that exceeds the
capacity for acute utilization in oxidative or biosynthetic
pathways leads to ectopic steatosis. To determine whether
the decreases in plasma TG had a measurable effect on the
integrated lipid exposure of nonadipose tissues over the
course of the 12 week treatment, we used proton MRS to
quantify hepatic TG noninvasively. Liver TG was chosen as

an endpoint rather than cardiac TG because the higher
liver TGs facilitate sensitive and accurate assessments of
systemic lipid exposure (44). There was no significant difference between the fenofibrate and placebo groups with
respect to change in liver fat percentage, whether the measures were analyzed before or after log transformation
(Fig. 2). There was also no difference in liver fat percentage or log delta-liver fat percentage after multivariate modeling. Because liver fat is typically a more sensitive measure
of ectopic lipid accumulation than myocardial fat (45), it is
unlikely that the fenofibrate and placebo groups would
have demonstrated differences in myocardial TG.
Excess FAs are also incorporated into the de novo synthetic
pathway for ceramides. While the ratio of C24:0 to C16:0 ceramide is inversely associated with incident heart failure (32),
it is not known how this measure is impacted by TG lowering.
Thus, we quantified the plasma C24:0 ceramide and C16:0
ceramide and calculated the C24:0/C16:0 ceramide ratio before and after treatment with fenofibrate. Fenofibrate treatment resulted in a significant lowering of the C24:0 ceramide
(P = 0.00073) and the ceramide ratio (P = 0.004) compared
with placebo treatment (Fig. 2, Table 4). After adjustment for
the predetermined baseline characteristics, this difference in
 C24:0/C16:0 ceramide ratio remained significant (P =
0.003). There were no significant correlations among delta
C24:0/C16:0 ceramide ratio, delta plasma TG, or delta liver
fat, with or without data transformation.

TABLE 3. Baseline medications (numbers of patients taking the medications)

Statin
Insulin
Metformin
Thiazolidinedione
Sulfonylurea
DPP-4 inhibitor
SGLT-2 inhibitor
GLP-1 agonist
Calcium channel blocker
Beta-blocker
ACE-inhibitor/ARB antagonist
Diuretics

Placebo
(n = 34)

Fenofibrate
(n = 31)

P

16
7
25
1
10
3
5
6
7
3
19
6

16
6
25
0
8
4
4
6
7
5
17
8

0.71
0.90
0.50
0.34
0.75
0.60
0.83
0.86
0.84
0.37
0.94
0.42
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However, there was no difference between the two treatment groups in the changes of the other oxidative stress
markers analyzed. There were also no differences in the
changes in well-established inflammatory markers, (TNF-,
IL-6, and hsCRP) between the groups.

Diastolic relaxation was inversely related to change in
plasma TG and directly related to change in plasma
C24:0/C16:0 ceramide ratio
As shown in Fig. 3 and Table 4, there were no significant
changes in systolic or diastolic functional measures after
treatment with fenofibrate, as compared with placebo. Specifically, there was no change in the primary endpoints: FS
or e′. However, there was a negative correlation between
the  TGs and LV relaxation as measured by  e′ average
(r = 0.25, P < 0.05). This suggests that TG lowering contributes to improved diastolic performance. On the other
hand, change in LV relaxation, as measured by e′, correlated directly with change in plasma C24:0/C16:0 ceramide
ratio (r = 0.26, P < 0.04). There was also a trend toward a
direct correlation between change in systolic function, as
measured by delta s′, with change in plasma C24:0/C16:0
ceramide ratio (r = 0.24, P = 0.056). These changes provide
evidence that the plasma ceramide ratio may have utility as
a plasma biomarker for cardiac function.

DISCUSSION
This randomized clinical trial was designed to evaluate
the effects of decreasing plasma TG on cardiac function
1070
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Fig. 2. Lipid alterations after placebo or fenofibrate intervention.
A: Serum TGs decreased more after fenofibrate treatment compared with after placebo (*P < 0.05). B: No significant change in
plasma FFAs. C: Lack of significant change in liver fat percentage
between the fenofibrate and placebo groups. D: The ratio of the
plasma C24:0/C16:0 ceramides decreased more after fenofibrate
treatment than after placebo (*P < 0.004).

and biomarkers of metabolic stress in patients with T2D. As
expected, fenofibrate, which increases plasma TG clearance and activates PPAR, significantly decreased plasma
TG. As compared with placebo, fenofibrate treatment did
not alter the primary cardiac function endpoints, FS, or e′.
Nonetheless, lowering of plasma TG across both groups
did relate to improvement of LV relaxation, as measured
by e′ average. This suggests that lowering systemic lipid exposure is beneficial for cardiac function.
We also evaluated secondary and tertiary outcomes related to biomarkers of cardiovascular risk and the pathogenesis of lipotoxicity. Fenofibrate treatment did not
change liver steatosis or markers of inflammation, and only
one of four markers of oxidative stress decreased significantly after fenofibrate treatment. On the other hand, we
observed a significant decrease in plasma C24:0/C16:0 ceramide ratio after fenofibrate treatment as compared with
placebo. Because the plasma ceramide ratio is inversely associated with incident CHD, heart failure, and death (32),
and because a lower plasma ceramide ratio is associated
with lower LV ejection fraction and diminished global circumferential strain (46), this finding is unanticipated, as
TG lowering would be expected to improve cardiovascular
risk (31). On the other hand, consistent with the hypothesis that decreasing C24:0/C16:0 ceramide ratios portend
worse cardiovascular outcomes, across all subjects in the
present study, decreases in this ratio related to a worsening
LV relaxation, as measured by a decrease in e′ average.
The association between TG lowering and improved cardiac function, regardless of treatment group, correlates
well with previous studies in animal models of T2D that
show that decreasing excessive fat delivery to the heart, or
exporting lipid from the heart, improves cardiac function
(11, 13). It also correlates well with the finding that in humans with obesity (and some with T2D) who underwent
gastric bypass-induced weight loss, plasma TG lowering was
accompanied by lowered total myocardial FA utilization
and oxidation as well as improved e′ average and E/e′ (47).
In the present study, we did not find association of treatment group with improvement in cardiac function or measures of ectopic steatosis. Based on our calculations of the
95% confidence bounds, we can be 95% sure that fenofibrate does not cause more than a 0.5 (centimeters per second) increase in e′ average and a 0.06 unit increase on FS
compared with placebo, which are relatively small changes.
Our failure to detect improved cardiac function in subjects
receiving fenofibrate may have related to duration of treatment (12 weeks) or sample size of the study (n = 65). Prior
studies have shown variable effects on cardiovascular outcomes with the addition of fenofibrate to lower TGs in patients with diabetes or metabolic syndrome. For example,
in the ACCORD lipid study, fenofibrate did not reduce
CHD or heart failure events in patients with T2D (30),
whereas the FIELD study showed that fenofibrate reduced
cardiovascular disease events in women with T2D (48).
These and other studies have focused on endpoints of hospitalization for CHD or heart failure and/or cardiovascular
deaths, whereas our study focused on LV function as an
outcome.

Ceramides are complex lipids with pleiotropic biological
effects (49). Depending on fatty acyl chain lengths, these
hydrophobic molecules differentially affect membrane
structure and function as well as number of signaling pathways in cells (14, 49). Although the effects of each ceramide

species is not completely understood, several lines of research now point to C16:0 as being involved in mitochondrial permeabilization and apoptosis (50) and linked to
all-cause mortality in community-based cohort studies (32).
In contrast, C24:0 ceramide appears to counteract the

TABLE 4. Changes in metabolic, inflammatory, and cardiovascular measures

2

 BMI (kg/m )
 Liver fat (%)
 Total cholesterol(mmol/l)
 LDL cholesterol (mmol/l)
 HDL cholesterol (mmol/l)
 TGs (mmol/l)
 Fasting FFAs (mmol/l)
 Fasting insulin (pmol/l)
 Fasting glucose (mmol/l)
 Glycated albumin (%)
 C24:0 ceramide
 C16:0 ceramide
 C24:0/C16:0 ceramide ratio
 hsCRP (mg/l)
 TNF- (pg/ml)
 IL-6 (pg/ml)

 Plasma N -(hexanoyl)-lysine (ng/ml)
 Plasma N-(propanoyl)-lysine (ng/ml)
 Urinary N-(hexanoyl)-lysine (ng/ml)
 Urinary N-(propanoyl)-lysine (ng/ml)
 Heart rate (bpm)
 Mean arterial pressure (mmHg)
 LV end-diastolic volume (ml)
 Relative wall thickness
 Ejection fraction (%)
 FS (%)
 Global longitudinal strain (%)a
 s′ average (cm/s)
 e′ average (cm/s)
 E/e′ septal

Placebo (n = 34)

Fenofibrate (n = 31)

P

0.21 ± 0.93
0.27 ± 3.40
0.21 ± 0.69
0.12 ± 0.61
0.02 ± 0.17
0.01 ± 0.67
0.01 ± 0.25
5.65 ± 65.37
0.11 ± 2.25
0.20 ± 1.63
0.045 ± 0.64
0.0029 ± 0.028
0.04 ± 2.44
0.03 ± 2.27
0.04 ± 0.68
1.01 ± 5.97
0.053 ± 0.035
0.737 ± 0.685
7.10 ± 24.66
44.73 ± 68.05
1.59 ± 8.86
0.3 ± 8.3
1.71 ± 10.87
0.02 ± 0.05
1.4 ± 4.8
0.030 ± 0.083
0.26 ± 2.02
0.16 ± 1.81
0.55 ± 1.58
0.21 ± 2.56

1.46 ± 7.71
1.71 ± 4.54
0.28 ± 0.62
0.13 ± 0.53
0.05 ± 0.22
0.31 ± 0.59
0.10 ± 0.25
10.18 ± 67.71
0.63 ± 1.82
0.43 ± 2.33
0.41 ± 0.36
0.0061 ± 0.27
1.6 ± 1.66
1.10 ± 2.94
0.32 ± 0.97
0.65 ± 3.52
0.059 ± 0.055
1.124 ± 0.720
15.85 ± 23.85
40.38 ± 76.31
1.58 ± 10.02
3.4 ± 8.8
0.52 ± 11.59
0.02 ± 0.04
3.1 ± 5.2
0.025 ± 0.090
0.23 ± 1.76
0.68 ± 1.04
0.02 ± 1.35
0.40 ± 3.13

0.24
0.16
0.004
0.08
0.60
0.048
0.14
0.78
0.31
0.66
0.00073
0.19
0.0036
0.11
0.09
0.17
0.65
0.03
0.65
0.81
1.000
0.15
0.43
0.74
0.19
0.80
0.96
0.17
0.13
0.79

Data are shown as Post-Pre, mean ± SD. Bold font indicates a significant P value. Outliers excluded: n = 1 in
fenofibrate group for  TG; n = 1 in fenofibrate group for  insulin; n = 3 (2 placebo, 1 fenofibrate) for  urinary
propanoyl-lysine. HOMA-IR, homeostatic model assessment of insulin resistance.
a
Placebo group, n = 27; fenofibrate group, n = 29 due to echocardiographic image limitations.
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Fig. 3. Relationships between cardiac function and metabolism changes. A: Change in FS after placebo or
fenofibrate (P = NS); box and whiskers (minimum–maximum) plot. B: Change in the e′ average after placebo
or fenofibrate (P = NS). C: Linear regression between  e′ and  TGs (r = 0.25, P < 0.05). D: Linear regression
between  e′ and  C24:0/C16:0 ceramide ratio (r = 0.26, P <0.04).

CONCLUSIONS
Decreasing plasma TG availability to the heart was associated with improved diastolic function in patients with T2D.
In contrast, decreasing plasma C24:0/C16:0 ceramide ratio
was associated with worsened diastolic function. Fenofibrate treatment did lower plasma TG, but it also lowered
plasma C24:0/C16:0 ceramide ratio. Given the positive associations of plasma ceramide ratios with improved survival
and lower incidence of CHD, this change may abate some
1072
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of the benefit from plasma TG lowering and warrants further study.
Limitations
Although fenofibrate treatment (n = 31) versus placebo (n = 34) did not alter the primary cardiac function
endpoints, there was a clear relationship between TG
lowering and cardiac function across both groups (n =
65). Failure to detect improvement in cardiac function
by treatment group, while still detecting a relationship
between plasma TG and cardiac function, could relate,
in part, to sample size. On the other hand, TG is more
likely to represent a barometer of the lipid overload
state, rather than a direct driver of lipotoxicity (54, 55).
Differences in baseline hsCRP between treatment groups
was noted, although we controlled for this in our analysis. The finding that fenofibrate treatment was associated with a decrease in plasma ceramide C24:0/C16:0
ratio does not automatically signify that fenofibrate is
associated with worse cardiac outcomes; for it is not
clear yet if low C24:0/C16:0 ceramide ratio is causally
linked or simply associated with worse outcomes. Further mechanistic research and interventional studies
are warranted. Finally, the findings of this study should
not be extended to patients who do not fit the study’s
entry criteria.
Data availability
The data for this study are in the tables and figures.
Individual de-identified data are available upon request
from Dr. Linda Peterson at lpeterso@wustl.edu and Ling
Chen, MD, MSPH, PhD at lingchen@wustl.edu in accordance with all data sharing policies of the National Institutes of Health and Washington University School of
Medicine. This trial was registered at clinicaltrials.gov as
NCT01752842.
The authors thank Kristin O’Callaghan for her editorial
assistance.
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